Human papillomavirus (HPV) causes disease not only in the genital tract, but also in the larynx. Within the larynx HPV 6/11 causes recurrent respiratory papillomatosis (RRP). RRP is relatively uncommon, yet it is devastating for the patient who requires many surgical procedures over years to control it. The cost of HPV-related genital tract disease is thought to be around £31 million per annum, whereas RRP costs in the region of £4 million annually despite RRP being comparatively rare. The HPV vaccination programme has brought great hope, although it is unfortunate that the current UK programme only targets high-risk HPV. Targeting both low- and high-risk HPV would have had additional benefits for the UK.
KashimaHK, ShahF, LylesA. A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis.Laryngoscope1992; 102: 9–13
SedlacekTV, LindheimS, EderC. Mechanism for human papillomavirus transmission at birth.Am J Obstet Gynecol1989; 161: 55–9
4.
DerkayCS. Task force on recurrent respiratory papillomas. A preliminary report.Arch Otolaryngol Head Neck Surg1995; 121: 1386–91
5.
CarrollCD, SaundersNC. Respiratory papillomatosis: a rare cause of collapse in a young adult presenting to the emergency department.Emerg Med J2002; 19: 362–5
HartleyC, HamiltonJ, BirzgalisAR, FarringtonWT. Recurrent respiratory papillomatosis – the Manchester experience, 1974-1992.J Laryngol Otol1994; 108: 226–9
8.
DraganovP, TodorovS, TodorovI, KarchevT, KalvatchevZ. Identification of HPV DNA in patients with juvenile-onset recurrent respiratory papillomatosis using SYBR Green real-time PCR.Int J Pediatr Otorhinolaryngol2006; 70: 469–73
9.
SmithEM, PignatariSS, GraySD, HaugenTH, TurekLP. Human papillomavirus infection in papillomas and nondiseased respiratory sites of patients with recurrent respiratory papillomatosis using the polymerase chain reaction.Arch Otolaryngol Head Neck Surg1993; 119: 554–7
10.
de SanjoséS, DiazM, CastellsaguéX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis.Lancet Infect Dis2007; 7: 453–9
11.
StrongMS, VaughanCW, CooperbandSR, HealyGB, ClementeMA. Recurrent respiratory papillomatosis: management with the CO2 laser.Ann Otol Rhinol Laryngol1976; 85 (4 Pt 1) 508–16
12.
LindebergH, ElbrondO. Laryngeal papillomas: the epidemiology in a Danish subpopulation 1965-1984.Clin Otolaryngol Allied Sci1990; 15: 125–31
13.
ShahK, KashimaH, PolkBF, ShahF, AbbeyH, AbramsonA. Rarity of cesarean delivery in cases of juvenile-onset respiratory papillomatosis.Obstet Gynecol1986; 68: 795–9
14.
LeeSL, HuiY. Recurrent respiratory papillomatosis in a survivor of extreme prematurity.Pediatr Pulmonal2004; 38: 352–4
15.
LoyoM, PaiSI, NettoGJ, TunkelDE. Aggressive recurrent respiratory papillomatosis in a neonate.Int J Pediatr Otorhinolaryngol2008; 72: 917–20
16.
SilverbergMJ, ThorsenP, LindebergH, GrantLA, ShahKV. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis.Obstet Gynecol2003; 101: 645–52
17.
KawanaK, YasugiT, YoshikawaH. Evidence for the presence of neutralizing antibodies against human papillomavirus type 6 in infants born to mothers with condyloma acuminata.Am J Perinatol2003; 20: 11–16
18.
Armbruster-MoraesE, IoshimotoLM, LeaoE, ZugaibM. Presence of human papillomavirus DNA in amniotic fluids of pregnant women with cervical lesions.Gynecol Oncol1994; 54: 152–8
19.
ReevesWC, RupareliaSS, SwansonKI, DerkayCS, MarcusA, UngerER. National registry for juvenile-onset recurrent respiratory papillomatosis.Arch Otolaryngol Head Neck Surg2003; 129: 976–82
20.
KashimaH, MountsP, LeventhalB, HrubanRH. Sites of predilection in recurrent respiratory papillomatosis.Ann Otol Rhinol Laryngol1993; 102 (8 Pt 1):580–3
GlazerG, WebbWR. Laryngeal papillomatosis with pulmonary spread in a 69–year-old man.Am J Roentgenol1979; 132: 820–2
23.
BenjaminB, ParsonsDS. Recurrent respiratory papillomatosis: a 10 year study.J Laryngol Otol1988; 102: 1022–8
24.
GabbottM, CossartYE, KanA, KonopkaM, ChanR, RoseBR. Human papillomavirus and host variables as predictors of clinical course in patients with juvenile-onset recurrent respiratory papillomatosis.J Clin Microbiol1997; 35: 3098–103
25.
ArmstrongLR, DerkayCS, ReevesWC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force.Arch Otolaryngol Head Neck Surg1999; 125: 743–8
GereinV, SoldatskiIL, BabkinaN, OnufrievaEK, BarysikN, PfisterH. Children and partners of patients with recurrent respiratory papillomatosis have no evidence of the disease during longterm observation.Int J Pediatr Otorhinolaryngol2006; 70: 2061–6
SternY, FelipovichA, CottonRT, SegalK. Immunocompetency in children with recurrent respiratory papillomatosis: prospective study.Ann Otol Rhinol Laryngol2007; 116: 169–71
30.
SchraffS, DerkayCS, BurkeB, LawsonL. American Society of Pediatric Otolaryngology members’ experience with recurrent respiratory papillomatosis and the use of adjuvant therapy.Arch Otolaryngol Head Neck Surg2004; 130: 1039–42
31.
LeventhalBG, KashimaHK, WeckPW. Randomized surgical adjuvant trial of interferon alfa-nl in recurrent papillomatosis.Arch Otolaryngol Head Neck Surg1988; 114: 1163–9
32.
DonneAJ, RotheraMP, HomerJJ. Scientific and clinical aspects of the use of cidofovir in recurrent respiratory papillomatosis.Int J Pediatr Otorhinolaryngol2008; 72: 939–44
33.
McMurrayJS, ConnorN, FordCN. Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study.Ann Otol Rhinol Laryngol2008; 117: 477–83
34.
DonneAJ, HampsonL, HeX, RotheraMP, HomerJJ, HampsonIN. Effects of cidofovir on a novel cell-based test system for recurrent respiratory papillomatosis.Head Neck2007; 29: 741–50
35.
DonneAJ, HampsonL, HeXT. Potential risk factors associated with the use of cidofovir to treat benign human papillomavirus-related disease.Antivir Ther2009; 14: 939–52
36.
FreedGL, DerkayCS. Prevention of recurrent respiratory papillomatosis: role of HPV vaccination.Int J Pediatr Otorhinolaryngol2006; 70: 1799–803
37.
SilverbergMJ, ThorsenP, LindebergH, Hdieh-GrantL, ShahKV. Clinical course of recurrent respiratory papillomatosis in Danish children.Arch Otolaryngol Head Neck Surg2004; 130: 711–16
38.
GoonP, SonnexC, JaniP, StanleyM, SudhoffH. Recurrent respiratory papillomatosis: an overview of current thinking and treatment.Eur Arch Otorhinolaryngol2008; 265: 147–51
39.
HarperDM, FrancoEL, WheelerC. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.Lancet2004; 364: 1757–65
40.
VillaLL, CostaRL, PettaCA. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.Lancet Oncol2005; 6: 271–8
41.
KoutskyLA, AultKA, WheelerCM. A controlled trial of a human papillomavirus type 16 vaccine.N Engl J Med2002; 347: 1645–51
42.
PerezG, Lazcano-PonceE, Hernandez-AvilaM. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women.Int J Cancer2008; 122: 1311–18
43.
SkjeldestadFE, MehtaV, SingsHL. Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics.Acta Obstet Gynecol Scand2008; 87: 81–8
44.
SchwarzTF. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.Adv Ther2009; 26: 983–98
45.
GianniniSL, HanonE, MorisP. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.Vaccine2006; 24: 5937–49
46.
SchafferA, BrothertonJ, BooyR. Do human papillomavirus vaccines have any role in newborns and the prevention of recurrent respiratory papillomatosis in children?J Paediatr Child Health2007; 43: 579–80
47.
MantC, KellB, RiceP, BestJM, BibleJM, CasonJ. Buccal exposure to human papillomavirus type 16 is a common yet transitory event of childhood.J Med Virol2003; 71: 593–8
48.
O'MahonyC. Government decision on national human papillomavirus vaccine programme is a sad day for sexual health.Sex Transm Infect2008; 84: 251
49.
LangleyPC, WhiteDJ, DrakeSM. The costs of treating external genital warts in England and Wales: a treatment pattern analysis.Int J STD AIDS2004; 15: 501–8
50.
LaceyCJ, GoodallRL, TennvallGR. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts.Sex Transm Infect2003; 79: 270–5
51.
LaceyCJ, LowndesCM, ShahKV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease.Vaccine2006; 24 (Suppl 3):S3/35–41
52.
PeytonSW, WiatrakB. Is cidofovir a useful adjunctive therapy for recurrent respiratory papillomatosis in children?Int J Pediatr Otorhinolaryngol2004; 68: 413–18
